Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients.
A decreased incidence of cancer of the prostate has been demonstrated in a cohort of 6168 chronic schizophrenic patients followed up from 1957 to 1984. A case-control study was performed based on this cohort to determine the possible influence of neuroleptic treatment and other factors on the risk of developing prostate cancer. Thirty-eight male schizophrenic patients who had developed prostate cancer during the observation period were compared with 76 age- and sex-matched controls from the same cohort. The only significant association was that of a reduced risk of prostate cancer among those who had been treated with a cumulative dose of high-dose phenothiazines (primarily chlorpromazine) of 15 g or more. These patients had been treated with an average daily dose of 145 mg chlorpromazine for an average of 12.5 years. No other significant risk factors were identified.
Mortensen
P B
PB
Institute of Psychiatric Demography, Aarhus Psychiatric Hospital, Risskov, Denmark.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002908:Chronic Disease; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003718:Denmark / Q000453:epidemiology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015994:Incidence; D008019:Life Style; D008297:Male; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000517:prevention & control* / Q000523:psychology; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology; D012565:Schizophrenic Psychology; D012803:Sick Role
D014150:Antipsychotic Agents; D002746:Chlorpromazine